Lv31
350 积分 2026-04-01 加入
The Impact of the Systemic Immune-inflammation Index and the Systemic Inflammatory Response Index on Progression-free Survival and Overall Survival in Second-line Immunotherapy for Metastatic Non-small Cell Lung Cancer
1小时前
求助中
Prognostic significance of pretreatment inflammatory response, immune and nutritional status in small cell lung cancer
1小时前
求助中
Evaluating inflammatory markers as predictive tools for advanced non-small cell lung cancer receiving nivolumab
1小时前
求助中
External validation of a clinical prediction model for mid-term mortality after video-assisted thoracoscopic surgery lobectomy for non-small cell lung cancer
1小时前
求助中
Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non‐small cell lung cancer patients with neoadjuvant immunotherapy
4天前
已完结
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
14天前
已完结
Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)
14天前
已完结
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407
14天前
已完结
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
14天前
已完结
皖公网安备34019202002308
